ARPA-H Launches Two New Programs
EMBODY: Engineering of Immune Cells Inside the Body
The goal of EMBODY is to radically alter how immune therapies are developed and delivered for life-threatening and chronic conditions by retraining healthy immune cells, and eliminating time, cost and access hurdles.
“By developing agents that target specific immune cell types, essentially providing instructions to cells already active inside your body, we hope to make advanced immunotherapies available close to home for Americans across the country,” said EMBODY Program Manager Daria Fedyukina, Ph.D., in ARPA-H’s recent program announcement.
PRINT (Personalized Regenerative Immunocompetent Nanotechnology Tissue)
PRINT intends to use state-of-the-art bioprinting technology and a regenerative medicine approach to 3D print personalized, on organs that will not require immunosuppressive drugs.
“By starting from multiple different types of cells, we will be creating organs that will be individually matched,” said PRINT Program Manager Ryan Spitler, Ph.D., in ARPA-H’s recent program announcement. “The body will not recognize it as a foreign entity, eliminating the need of immunosuppressive drugs, which has never been done in the history of organ transplantation.”
To learn more about both programs, including how to register for the upcoming Proposers’ Days, visit the EMBODY program page and PRINT program page
- Androgen signaling restricts glutaminolysis to drive sex-specific Th17 metabolism in … – JCI
Viewing as Journal of Clinical Investigation. Not your institution? ResearchIn-Press PreviewImmunologyPulmonology Open Access | 10.1172/JCI177242. - MARAbio: Precision Immunology Company Raises $19 Million (Series A)
MARAbio Systems – a precision immunology company whose mission is to detect, treat and prevent Maternal Autoantibody Related Autism – announced it … - Advances in Trop-2 Targeted Antibody-Drug Conjugates for Breast Cancer – Frontiers
Toll-Like Receptor Signaling Pathways. Takumi Kawasaki; Taro Kawai. Frontiers in Immunology. doi 10.3389/fimmu.2014.00461. 395,842 views; 2,565 … - New test improves diagnosis of allergies | ScienceDaily
… Immunology, Bern University Hospital, and Prof. Dr. Thomas Kaufmann … The study was recently published in the European Journal for Allergy and … - Teva adopts biotech ethos as it leans into innovative drug development, exec says
… immunology. There's the company's long-acting injectable formulation of the nearly two-decade-old antipsychotic olanzapine, which Hughes says …